ALK-Abelló A/S Stock price

Equities

ALK B

DK0061802139

Pharmaceuticals

Market Closed - Nasdaq Copenhagen 11:59:49 2024-03-18 am EDT 5-day change 1st Jan Change
129.2 DKK +1.41% Intraday chart for ALK-Abelló A/S -0.39% +27.67%
Sales 2024 * 5.34B 777M Sales 2025 * 5.89B 858M Capitalization 28.58B 4.16B
Net income 2024 * 763M 111M Net income 2025 * 1.07B 156M EV / Sales 2024 * 5.31 x
Net cash position 2024 * 257M 37.4M Net cash position 2025 * 1.09B 158M EV / Sales 2025 * 4.67 x
P/E ratio 2024 *
36.3 x
P/E ratio 2025 *
27.4 x
Employees 2,824
Yield 2024 *
-
Yield 2025 *
-
Free-Float 58.99%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on ALK-Abelló A/S

1 day+1.41%
1 week-0.39%
Current month+0.54%
1 month+0.78%
3 months+31.84%
6 months+57.95%
Current year+27.67%
More quotes
1 week
126.30
Extreme 126.3
130.70
1 month
126.30
Extreme 126.3
134.50
Current year
98.50
Extreme 98.5
134.50
1 year
69.90
Extreme 69.9
134.50
3 years
69.90
Extreme 69.9
175.00
5 years
52.70
Extreme 52.7
175.00
10 years
29.25
Extreme 29.25
175.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 45 Dec. 31
Director of Finance/CFO 52 23-05-31
Chief Tech/Sci/R&D Officer - 23-02-28
Members of the board TitleAgeSince
Director/Board Member 57 21-03-17
Chairman 63 20-03-10
Director/Board Member 64 15-03-11
More insiders
Date Price Change Volume
24-03-18 129.2 +1.41% 176,659
24-03-15 127.4 -1.39% 186,142
24-03-14 129.2 -0.92% 154,417
24-03-13 130.4 -0.31% 171,247
24-03-12 130.8 +0.85% 276,380

Delayed Quote Nasdaq Copenhagen, March 18, 2024 at 11:59 am EDT

More quotes
ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Company's allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
129.2 DKK
Average target price
125 DKK
Spread / Average Target
-3.25%
Consensus
  1. Stock
  2. Equities
  3. Stock ALK-Abelló A/S - Nasdaq Copenhagen